Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): Results from a phase 3, randomised, open‐label, efficacy assessor‐blinded clinical trial

Published 2020 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): Results from a phase 3, randomised, open‐label, efficacy assessor‐blinded clinical trial
Authors
Keywords
-
Journal
BRITISH JOURNAL OF DERMATOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-06-28
DOI
10.1111/bjd.19341

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.